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Abstract 
Review on t(14;16)(q32;q23) IGH/MAF, with data 
on clinics, and the genes involved. 
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Identity 
Note 
t(14;16)(q32;q23) represents 14q32/IGH 
rearrangement and belongs to the group of 
IGH/MAF translocations (rearrangements of the 
genes from the MAF oncogene family MAF, MAFA 
and MAFB with the IGH locus). As the other two 
IGH/MAF translocations t(8;14)q24;q32) 
andt(14;20)(q13;32) is described only in plasma cell 
neoplasms (PCN). t(14;16)(q32;q23) resulted in the 
juxtaposition of the oncogene MAF ( located at 
16q23) to the strong enhancer of the IGH gene 
(located at 14q32) causing its up regulation in the 
plasma cells. This anomaly is found in both multiple 
myeloma (MM) and its precursor monoclonal 
gammapathy of undetermined significance (MGUS) 
respectively in 5% (Avet-Loiseau et al, 2007; 
Fonseca et al, 2009) and 1-5% (Avet-Loiseau et al, 
2002; Fonseca et al, 2002) of the cases with 14q32 
rearrangements . The anomaly is cryptic and 
therefore in the routine practice is determinated by 
fluorescent in situ hybridization with DNA specific 
probes and/or by qPCR technique. It is difficult to be 
proved with the classical G-banding technique and 
because of this only a small number of cases with 
karyotypic description of t(14;16) have been 
reported. 
Clinics and pathology 
Disease 
Multiple myeloma (MM) 
Phenotype/cell stem origin 
t(14;16) is generated during B-cell maturation in 
germinal centers possibly as a result of errors in the 
IGH switch recombination (Bergsagel et al, 2001). 
The anomaly appears to be an early event in the 
genesis of plasma cell neoplasms (PCN) as it occurs 
in both MGUS and MM. 
Epidemiology 
t(14;16) is described in 12 cases (Mitelman 
database) (0.6% of all MM cases with abnormal 
karyotypes) (Gabrea et al, 2008; Le Baccon et al, 
2001; Lioveras et al, et al, 2004; Mohamed et al, 
2007;  Rack et al, 2016; Sawyer et al, 1998; Sawyer 
et al, 2014; Smadja et al, 2003). Examinations of the 
large series with MM (cytogenetic diagnosis 
included IGH-MAF fusion probe) showed that the 
frequency of t(14;16) is very low - 2.2-3.2% of all 
MM cases (Avet-Loiseau et al, 2010; Pavlistova et 
al, 2017; Mickova et al, 2013). The sex ratio is 
M:F=1.4:1 and the anomaly has been observed only 
in older patients (4 cases documented: average age 
62 years; range 55-72 years). The presented median 
age is in agreement with the data of the median 
patients age of the largest series with t(14;16) 
positive MM cases (32) reported by Avet-Loiseau et 
al, 2010 (63 years; range 45-75 years). 
Clinics 
It has been suggested that t(14;16) positive MM 
cases are associated with less frequent 
extramedullary tumor formation and negativity for 






Atlas Genet Cytogenet Oncol Haematol. 2019; 23(5) 130 
 
CD56 expression. In the cases with t(14;16) is found 
also higher frequency of the IgG subtype M protein, 
leukocytosis, thrombocytemia, hypercalcemia and 
lower frequency of hypocalcemia compared with 
those without t(14;16) (Narita et al, 2015). The cases 
with t(14;16) are resistant to bortezomib therapy, 
because proteasome inhibitors abrogate glycogen 
synthase kinase 3 beta - mediated degradation of  
MAF protein leading to its stabilization (Qiang et al,  
2016) 
Cytogenetics 
All reported cases presented in Mitelman database 
except one (with isolated t(14;16)) are with complex 
karyotypes. Two of them are with hyper-diploid, two 
with pseudo-diploid and six with hypo-diploid 
karyotypes. The cases with hyper-diploid karyotypes 
included trisomy of chromosome 3, 9, 15, 18, 19, 20 
and 21 and the cases with hypo-diploid karyotypes 
the loss of chromosome 4, 11, 13, 16,-18, 20 and 22. 
All cases with complex karyotypes are associated 
with structural abnormalities of chromosome 1 and 
all except one with abnormalities of chromosome 13. 
Chromosome 1 anomalies are presented 
predominantly with unbalanced translocations 
including whole arm translocations with the partner 
chromosomes 4, 5, 8, 15, 16, 18, 19, 20 and 22. In 
most of the cases the breakpoint in chromosome 1 is 
in the region 1q10-21. Four cases have deletions of 
the short arm of chromosome 1 in the region 1p11-
33 and in two cases additional material of unknown 
origin is attached to the bands 1q21 and 1p22. The 
abnormalities of chromosome 13 included 
monosomy of chromosome 13 in six cases and 13q 
deletions (in the region 13q12-22) in three cases. 
Deletions of 17p12 is found in two cases and 
numerical anomalies of the sex chromosomes in four 
cases (three cases with -Y and one with -X). The 
presented information of the additional anomalies 
are partially in agreement with the findings of the 
large cytogenetic series with MM carrying t(14;16). 
The most common additional abnormalities in these 
series are -13/13q-, amplification of 1q, trisomy or 
tetrasomy of chromosome 15 and structural (mostly 
deletions of the short arm in the region 8p21.3) and 
numerical of chromosome 8. Coincidence of both 
anomalies t(4;14) and t(14;16) is not observed 
(Avet-Loiseau et al, 2010; Kadam Amere et al, 2016; 
Mickova et al, 2013). 
Disease 
Plasma cell leukemia 
Epidemiology 
Two cases are reported (53 and 55 years old males) 
(Avet-Loiseau et al., 2001; Stella et al, 2011). 
Cytogenetics 
Both cases showed complex karyotypes: one with 
hyperdiploid and numerical anomalies ( +8, +9, +18 
and -13) and the other with hypodiploid karyotype 
and numerical (-Y, -7, -8, -13, -14 and +21) and 
structural anomalies, including 1q rearrangements. 
Prognosis 
There is controversy about the prognostic value of 
t(14;16). Negative impact on prognosis has been 
suggested by Fonseca et al., 2003 and Nair et al, 
2010. Pavlistova et al, 2017 identified that the 
median overall survival (OS) was shorter in 
comparison with the control group, but was not 
statistically significant. Avet-Loiseau et al, 2010 
reported that by univariate analysis t(14;16) is not 
prognostic to age, beta2-microglobulin level, t(4;14), 
del(17p) and del(13q) and in multivariate analysis, 
the p value associated with t(14;16) is even less 
significant. The authors also found no difference for 
OS. Because of the contradictory data larger number 
of cases carrying t(14;16) is needed to establish the 
real prognostic relevance of t(14;16). 
Genetics 
Note 
The predisposing factors leading to the appearance 
of the myeloma associated 14q32 rearrangements 
including t(14;16) are still unknown. The formation 
of the 14q32 rearrangements requires nuclear co-
localization of the IGH with the partner genes 
involved in the 14q32 translocations, respectively in 
the case of t(14;16) - nuclear co-localization of IGH 
with MAF. But the 3D FISH experiments provided 
by Martin et al, 2013 indicated that the MAF and 
IGH are not co-localized in the nucleus of the non-
malignant B cells. In these cells MAF is located 
more peripherally in the nucleus while IGH occupies 
more central nuclear position. Obviously, in order 
for MAF to reach the nuclear position of IGH, large 
chromatin decondensation in the region of its locus 
is necessary to occur. The latter could be a 
consequence of an ectopic expression of the MAF 
gene. As is noted below, MAF is activated by 
ERK/MEK pathway probably as a result of RAS or 
BRAF mutations but these mutations are late event 
in MM. One possible activator of MAF in the stage 
of B-cell maturation in germinal centers could be the 
small MAF protein BATF. This transcription factor 
is responsible for the differentiation of the follicular 
T-helper cells controlling the expression of both 
BCL6 and MAF. In B-cells BATF is involved in 
class-switch recombination (CSR) controlling 
directly the expression of both activation-induced 
cytidine deaminase and IH-CH germline transcripts 
(Ise et al, 2011). It has been shown also that BATF 
induced high level of the T-bet expression through 
chromatin remodelling promoting effector 
differentiation and cell survival (Kuroda et al, 2011). 
However, one possible BATF induced activation of 
MAF required additional chromatin deregulation of 
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the MAF locus (to be achieved open chromatin 
structure), because MAF is silent in mature B-cells. 
But if an ectopic MAF expression is occurred during 
an ineffective CSR (existence of unrepaired double-
strand DNA breaks in the switch regions of IGH) 
would be at high risk for the appearance of t(14;16). 









MAF is a member of the basic leucine zipper 
transcription factors belonging to the AP1 
superfamily that includes the JUN, FOS, ATF, 
CREB and MAF family. MAF encodes two protein 
isoforms which differ in their carboxy-terminus - 
MAF short and long form (have 30 extra amino-
acids). As the other large Maf proteins (MAFA,-
MAF, MAFB and NRL), MAF contains the b-Zip 
domain, as well as an additional amino-terminal 
transactivation domain (Eychene & Pouponnot, 
2009-11). MAF gene plays a role in the embryonic 
lens fiber cell development and its germinal 
mutation is responsible for congenital cataract in 
humans. The MAF target genes are CCND2 (cyclin 
D2), ITGB7 (integrin beta7) and CCR1 (C-C 
chemokin receptor 1). All three genes are up-
regulated by MAF protein and have an important 
role in MM for the cell cycle progression (cyclin D2) 
and adhesion of the myeloma cells to bone marrow 
stroma cells (integrin beta 7 and CCR1) (Hurt et al, 
2004).  Additionally, in MM cases integrin beta 7 
binds to CDH1 (E-cadherin) on the surface of stroma 
cells and increases the production of VEGFA 
(vascular endothelial growth factor) which resulted 
in enhanced bone marrow angiogenesis and 
autocrine and paracrine stimulation of the myeloma 
cells (Podar et al, 2001;  2002). MAF is expressed in 
many tissues including neural tissues, small 
intestine, skin and kidney. In the normal 
hematopoietic tissue MAF is expressed only in the 
nuclei of T helper 2 (TH2) cells, monocytes and 
macrophages, controlling the expression of IL4 and 
IL10 (interleukin 4 and 10) (Cao et al, 2005; Kim et 
al, 1999), while in the plasmocytes MAF mRNA is 
not expressed (Natkunam et al, 2009). It has been 
reported that MAF is up-regulated in B, T, NK-cell 
neoplasms, myeloma cell lines and approximately in 
50% of the MM cases lacking t(14;16) translocation 
(Hurt et al, 2004; Natkunam et al, 2009).  
Based on the finding that the inhibition of the MEK-
ERK pathway reduced the MAF transcription in cell 
lines and MM cases with MAF overexpression, 
Annunziata et al, 2011 proposed that the MAF up 
regulation in MM cases lacking t(14;16) is possibly 
caused by the activation of MEK-ERK signalling 
cascade.  
The latter is in agreement with the observation that 
MAF is overexpressed in the hairy cell leukemia 
(HCL) (Natkunam et al, 2009) where the causal 
genetic event is the BRAF-V600E mutation (Arcaini 
et al 2012). As in HCL in MM aberrant MEK-ERK 
pathway is also found. Mutations of KRAS, NRAS 
and BRAF are detected in up to 50% of the newly 
diagnosed MM patients, but it has been shown that 
only KRASG12D and BRAFV600E are consistently 
associated with ERK activation (Xu et al, 2017). It is 
logical to expect that in MM with these two 
mutations MAF will be overexpressed. 
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